CD8A and head and neck squamous cell carcinoma: It has demonstrated its ability to induce selective binding, activation and expansion of HPV16 E711-20-specific CD8+ T cells in an animal model, and is currently being evaluated as a monotherapy and in combination with pembrolizumab in HPV16-positive HNSCC (NCT03978689).